echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > CStone Pharmaceuticals Announces Successful Sale of US$200 Million Equity to Pfizer

    CStone Pharmaceuticals Announces Successful Sale of US$200 Million Equity to Pfizer

    • Last Update: 2020-10-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Pharma.com, Oct. 13 (Xinhua) -- Cornerstone Pharmaceuticals announced today that a share subscription agreement signed between Pfizer's subsidiaries and its subsidiaries has been completed, and Pfizer has successfully subscribed for a new stake in Cornerstone Pharmaceuticals with a total price of approximately US$200 million (approximately HK$1.55 billion).
    also marks the official entry into force of the multi-directional strategic cooperation announced by the two sides on September 30, 2020.
    Pfizer's 115,928,803 shares, which were subscribed for at about HK$13.37 per share, were approved for listing by the Listing Committee of the Stock Exchange of Hong Kong.
    Pfizer bought about 9.9 per cent of Keystone Pharmaceuticals' total share value issued after the rights issue.
    equity subscription is part of the strategic cooperation framework between Cornerstone Pharmaceuticals and Pfizer, which will further transform Keystone Pharmaceuticals into a fully capable biopharmaceutical company by achieving its strategic, commercial and financial objectives.
    the completion of the equity subscription also allows the two sides to continue to advance a series of initiatives within the framework of the partnership: Pfizer's exclusive commercial rights to Shugli's single-resistance at Chinese mainland.
    Schugli monoantigen is a PD-L1 monoclonal antibody developed by Keystone Pharmaceuticals, a core tumor product in the late stage of development.
    and Pfizer will work together to develop and commercialize other cancer products in Greater China.
    Andersk Pharmaceuticals and Pfizer can also selectively jointly introduce other cancer products in Greater China.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.